Gejyo F, Kawaguchi Y, Hara S, Nakazawa R, Azuma N, Ogawa H, Koda Y, Suzuki M, Kaneda H, Kishimoto H, Oda M, Ei K, Miyazaki R, Maruyama H, Arakawa M and Hara M: Arresting dialysis-related amyloidosis: a prospective multicenter controlled trial of direct hemoperfusion with a beta2-microglobulin adsorption column. Artif Organs, 28: 371-380, 2004.
Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R and Pisoni RL: Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet, 388: 294-306, 2016.
Hoshino J, Yamagata K, Nishi S, Nakai S, Masakane I, Iseki K and Tsubakihara Y: Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010. Nephrol Dial Transplant, 31: 595-602, 2016.
Wakasugi M, Kazama JJ, Yamamoto S, Kawamura K and Narita I: Cause-specific excess mortality among dialysis patients: comparison with the general population in Japan. Ther Apher Dial, 17: 298-304, 2013.
Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y and Niwa T: Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem, 403: 1841-1850, 2012.